$MBOT
Microbot Medical Inc. Stock $mbot

$mbot Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000119312513324514 Filed on August 07, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$38.00K	$33.00K	$249.0K
YoY Change	-85.61%	-86.75%	8.26%
Cost Of Revenue	$85.74K	$77.57K	$64.00K
YoY Change	19.09%	21.21%	28.0%
Gross Profit	$239.0K	$204.1K	$184.6K
YoY Change	24.44%	10.6%	2.53%
Gross Profit Margin	629.08%	618.56%	74.12%
Selling, General & Admin	$1.711M	$1.582M	$1.775M
YoY Change	4.54%	-10.92%	-15.46%
% of Gross Profit	715.65%	774.78%	961.95%
Research & Development	$5.184M	$4.805M	$3.749M
YoY Change	49.06%	28.16%	-25.76%
% of Gross Profit	2168.75%	2353.91%	2031.39%
Depreciation & Amortization	$260.0K	$230.0K	$250.0K
YoY Change	8.33%	-8.0%	-16.67%
% of Gross Profit	108.76%	112.68%	135.46%
Operating Expenses	$6.628M	$6.131M	$5.534M
YoY Change	25.79%	10.79%	-22.71%
Operating Profit	-$6.656M	-$6.221M	-$5.350M
YoY Change	31.1%	16.29%	-23.36%
Interest Expense	$382.1K	$392.9K	$14.18K
YoY Change	3254.27%	2671.46%	-99.53%
% of Operating Profit
Other Income/Expense, Net	-$535.6K	$352.6K	$6.183M
YoY Change	-95.24%	-94.3%	-15558.19%
Pretax Income	-$7.190M	-$5.870M	$830.0K
YoY Change	-56.0%	-807.23%	-120.54%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$7.192M	-$5.869M	$833.0K
YoY Change	-55.98%	-804.52%	-120.62%
Net Earnings / Revenue	-18925.4%	-17783.88%	334.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$239.7M	-$293.5M	$41.50M
COMMON SHARES
Basic Shares Outstanding	41.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.96M	$24.18M	$8.900M
YoY Change	-3.59%	171.69%	-43.17%
Cash & Equivalents	$20.96M	$22.75M	$7.203M
Short-Term Investments	$0.00	$1.430M	$1.700M
Other Short-Term Assets	$110.6K	$704.0K	$1.190M
YoY Change	-90.63%	-40.84%	10.19%
Inventory
Prepaid Expenses	$464.5K	$569.0K
Receivables	$125.5K	$68.47K	$120.0K
Other Receivables	$490.0K	$420.0K	$190.0K
Total Short-Term Assets	$22.20M	$25.99M	$10.41M
YoY Change	-4.48%	149.71%	-39.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.439M	$3.451M	$1.680M
YoY Change	253.16%	105.41%	-25.33%
Goodwill	$1.973M	$1.855M
YoY Change
Intangibles	$1.673M	$1.654M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$999.8K	$1.054M	$1.050M
YoY Change	-2.93%	0.37%	-45.6%
Total Long-Term Assets	$10.12M	$8.057M	$6.540M
YoY Change	57.59%	23.2%	-27.89%
TOTAL ASSETS
Total Short-Term Assets	$22.20M	$25.99M	$10.41M
Total Long-Term Assets	$10.12M	$8.057M	$6.540M
Total Assets	$32.32M	$34.05M	$16.95M
YoY Change	8.96%	100.9%	-35.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.861M	$3.022M	$760.0K
YoY Change	93.81%	297.57%	-43.7%
Accrued Expenses	$2.304M	$1.918M	$3.290M
YoY Change	-18.6%	-41.71%	7.17%
Deferred Revenue
YoY Change
Short-Term Debt	$3.600M	$2.610M	$0.00
YoY Change
Long-Term Debt Due	$178.8K	$213.8K	$200.0K
YoY Change	-14.88%	6.88%	-16.67%
Total Short-Term Liabilities	$8.062M	$7.822M	$4.280M
YoY Change	99.07%	82.75%	-8.74%
LONG-TERM LIABILITIES
Long-Term Debt	$9.900M	$17.50K	$230.0K
YoY Change	5110.53%	-92.39%	-46.51%
Other Long-Term Liabilities	$10.79M	$10.47M	$7.080M
YoY Change	-33.35%	47.88%	63.13%
Total Long-Term Liabilities	$20.69M	$17.50K	$7.310M
YoY Change	26.31%	-99.76%	53.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.062M	$7.822M	$4.280M
Total Long-Term Liabilities	$20.69M	$17.50K	$7.310M
Total Liabilities	$28.76M	$25.29M	$11.59M
YoY Change	40.75%	118.24%	22.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$380.6M	-$373.4M
YoY Change
Common Stock	$384.0M	$382.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.561M	$8.758M	$5.360M
YoY Change
Total Liabilities & Shareholders Equity	$32.32M	$34.05M	$16.95M
YoY Change	8.96%	100.9%	-35.6%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$7.192M	-$5.869M	$833.0K
YoY Change	-55.98%	-804.52%	-120.62%
Depreciation, Depletion And Amortization	$260.0K	$230.0K	$250.0K
YoY Change	8.33%	-8.0%	-16.67%
Cash From Operating Activities	-$6.000M	-$3.780M	-$5.090M
YoY Change	41.84%	-25.74%	-10.86%
INVESTING ACTIVITIES
Capital Expenditures	-$2.140M	-$2.100M	-$20.00K
YoY Change		10400.0%	-80.0%
Acquisitions
YoY Change
Other Investing Activities	$1.430M	$8.390M	$440.0K
YoY Change	-133.03%	1806.82%	-177.19%
Cash From Investing Activities	-$710.0K	$6.290M	$440.0K
YoY Change	-83.64%	1329.55%	-164.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.910M	13.00M	2.400M
YoY Change	-71.25%	441.67%	-1946.15%
NET CHANGE
Cash From Operating Activities	-6.000M	-3.780M	-5.090M
Cash From Investing Activities	-710.0K	6.290M	440.0K
Cash From Financing Activities	4.910M	13.00M	2.400M
Net Change In Cash	-1.800M	15.51M	-2.250M
YoY Change	-121.15%	-789.33%	-65.49%
FREE CASH FLOW
Cash From Operating Activities	-$6.000M	-$3.780M	-$5.090M
Capital Expenditures	-$2.140M	-$2.100M	-$20.00K
Free Cash Flow	-$3.860M	-$1.680M	-$5.070M
YoY Change	-8.75%	-66.86%	-9.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41304250	shares
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7203428
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.70
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	443926	shares
CY2013Q1	us-gaap	Restructuring Reserve RestructuringReserve	505000
CY2009Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	5135000
CY2009Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	36000
CY2009Q1	stem	Business Acquisition Cost Of Acquired Entity Purchase Price Net BusinessAcquisitionCostOfAcquiredEntityPurchasePriceNet	5135000
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	193177
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41260461	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41260461	shares
CY2013Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.06	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.85
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	440126	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9601378	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.00
CY2013Q2	us-gaap	Shares Issued SharesIssued	329131	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Loans Payable Current LoansPayableCurrent	2609954
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1917581
CY2013Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	7141
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17500
CY2013Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	12475042
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3021521
CY2013Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	6976234
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7821594
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-35090
CY2013Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	9011
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	8757985
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	381756774
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-373376304
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	23597
CY2013Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	654961
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1920902
CY2013Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1753349
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	412605
CY2013Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	28050
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34052165
CY2013Q2	us-gaap	Liabilities Liabilities	25294180
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	71323
CY2013Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	8277443
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	213750
CY2013Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1426061
CY2013Q2	us-gaap	Assets Current AssetsCurrent	25994890
CY2013Q2	us-gaap	Goodwill Goodwill	1855117
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24178531
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1654085
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1053850
CY2013Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	568968
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	263000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	234000
CY2013Q2	us-gaap	Assets Assets	34052165
CY2013Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1699503
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22752895
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	68472
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	263000
CY2013Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	55964
CY2013Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	100000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3939612
CY2013Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	43255
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	704041
CY2013Q2	us-gaap	Other Receivables OtherReceivables	418489
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	262000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	255000
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5301000
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	24178956
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3450968
CY2013Q2	stem	Carrying Value Of Purchased Loans CarryingValueOfPurchasedLoans	9512000
CY2013Q2	stem	Fair Value Of Warrant Liability FairValueOfWarrantLiability	8277443
CY2013Q2	stem	Finite Lived Intangible Acquired Assets FiniteLivedIntangibleAcquiredAssets	64000
CY2013Q2	stem	Fair Value Allocated To Warrant FairValueAllocatedToWarrant	388000
CY2013Q2	stem	Deposits And Other Long Term Liabilities DepositsAndOtherLongTermLiabilities	367726
CY2013Q2	stem	Outstanding Principal Amount Of Long Term Debt OutstandingPrincipalAmountOfLongTermDebt	231000
CY2013Q2	stem	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2013Q2	stem	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	425
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13311261
CY2011Q4	stem	Impairments Of Intangible Asset Finite Lived ImpairmentsOfIntangibleAssetFiniteLived	655000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37506305	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37506305	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2707441
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	6888
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	125000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	999365
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5097132
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	193177
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	12646
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	13984617
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	374507552
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-361091175
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	74426
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1389342
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	375063
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30170277
CY2012Q4	us-gaap	Liabilities Liabilities	16185660
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	79736
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	206250
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13900678
CY2012Q4	us-gaap	Assets Current AssetsCurrent	24041317
CY2012Q4	us-gaap	Goodwill Goodwill	1983426
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	22373309
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1822904
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	947301
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	537590
CY2012Q4	us-gaap	Assets Assets	30170277
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14339896
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8471275
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110159
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	820827
CY2012Q4	us-gaap	Other Receivables OtherReceivables	200788
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	22371953
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1375329
CY2012Q4	stem	Fair Value Of Warrant Liability FairValueOfWarrantLiability	9265365
CY2012Q4	stem	Deposits And Other Long Term Liabilities DepositsAndOtherLongTermLiabilities	216439
CY2012Q4	stem	Accrued Wind Down Expenses Current AccruedWindDownExpensesCurrent	1102762
CY2012Q4	stem	Outstanding Principal Amount Of Long Term Debt OutstandingPrincipalAmountOfLongTermDebt	331000
CY2012Q4	stem	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1356
CY2012Q4	stem	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
	dei	Trading Symbol TradingSymbol	STEM
	dei	Entity Registrant Name EntityRegistrantName	STEMCELLS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000883975
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P3Y
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38966547	shares
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13026000
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	458922
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18569
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14288215
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	100000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	8636
	us-gaap	Stock Issued1 StockIssued1	600006
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	106548
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-230048
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-34401
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	193283
	us-gaap	Net Income Loss NetIncomeLoss	-12285129
	us-gaap	Debt Issuance Costs DebtIssuanceCosts	117000
	us-gaap	Interest Expense InterestExpense	403003
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4911627
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	38500
	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.02	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10430088
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M18D
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9994467
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9368780
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2086
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12478412
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	34946
	us-gaap	Unrealized Gain On Securities UnrealizedGainOnSecurities	425
	us-gaap	Interest Paid InterestPaid	110266
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	330351
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3382
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	228267
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	100000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2420430
	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	9900000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1781
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y2M12D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13685651	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant estimates include the following:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="1%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">the grant date fair value of stock-based awards recognized as compensation expense (see Note 5, “Stock-Based Compensation”);</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="1%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">accrued wind-down expenses (see Note 6, “Wind-Down Expenses”);</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="1%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">the fair value of warrants recorded as a liability (see Note 9, “Warrant Liability”); and</font></p> </td> </tr> </table> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td width="1%"><font size="1"> </font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">•</font></td> <td valign="top" width="1%"><font size="1"> </font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">the fair value of goodwill and other intangible assets (see Note 4, “Goodwill and Other Intangible Assets”).</font></p> </td> </tr> </table> </div>
	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	one year LIBOR rate plus two percent
	us-gaap	Debt Instrument Interest Rate Increase Decrease DebtInstrumentInterestRateIncreaseDecrease	0.01	pure
	us-gaap	Revenues Revenues	565897
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-76763
	us-gaap	Gross Profit GrossProfit	421483
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-12513396
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	549603
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	471558
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1436223
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1292596
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-569081
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14723836
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	144414
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	9783094
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-57758
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	460762
	us-gaap	Share Based Compensation ShareBasedCompensation	1436223
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-128309
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1165000
	us-gaap	Operating Expenses OperatingExpenses	12899895
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3469278
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-6595
	stem	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	392057
	stem	Loan Fees LoanFees	1000000
	stem	Reducing Lieu Of Cash Payments ReducingLieuOfCashPayments	50000
	stem	Term Of Operating Lease TermOfOperatingLease	P15Y
	stem	Payments Creditable Against Royalties PaymentsCreditableAgainstRoyalties	50000
	stem	Cash And Cash Equivalents Maturity Period CashAndCashEquivalentsMaturityPeriod	P90D
	stem	Increase Decrease In Accrued Interest And Other Receivables IncreaseDecreaseInAccruedInterestAndOtherReceivables	68912
	stem	Fair Value Measurement With Directly Or Indirectly Observable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithDirectlyOrIndirectlyObservableInputsReconciliationRecurringBasisLiabilitySettlements	100000
	stem	Share Based Compensation Impact On Basic And Diluted Earnings Per Share ShareBasedCompensationImpactOnBasicAndDilutedEarningsPerShare	0.04
	stem	Increase Decrease In Accrued Wind Down Expenses IncreaseDecreaseInAccruedWindDownExpenses	1102762
	stem	Number Of Share Based Equity Incentive Plan NumberOfShareBasedEquityIncentivePlan	2	Incentive_Plan
	stem	Finite Lived Intangible Assets Foreign Currency Translation FiniteLivedIntangibleAssetsForeignCurrencyTranslation	-226336
	stem	Long Term Debt Bond Interest Rate LongTermDebtBondInterestRate	0.095	pure
	stem	Sale Value Of Common Stock SaleValueOfCommonStock	30000000
	stem	Debt Instrument Amortized Discount Percentage DebtInstrumentAmortizedDiscountPercentage	0.090	pure
	stem	Amortization Of Debt Discount And Debt Issuance Costs AmortizationOfDebtDiscountAndDebtIssuanceCosts	91450
	stem	Fair Value Measurement With Directly Or Indirectly Observable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithDirectlyOrIndirectlyObservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	65776
	stem	Wind Down Expenses WindDownExpenses	61837
	stem	Continuing Value Of Patent ContinuingValueOfPatent	0
	stem	Maturity Period Of Long Term Debt MaturityPeriodOfLongTermDebt	2014-08
	stem	Revenue From Licensing Agreements And Grants RevenueFromLicensingAgreementsAndGrants	106975
	stem	Expiry Period Of Lease Term ExpiryPeriodOfLeaseTerm	2013-06-30
	stem	Debt Instrument Period During Which Loan Is Subject To Interest Only Payments DebtInstrumentPeriodDuringWhichLoanIsSubjectToInterestOnlyPayments	P6M
	stem	Debt Instrument Period During Which Loan Is Subject To Principal And Interest Payments DebtInstrumentPeriodDuringWhichLoanIsSubjectToPrincipalAndInterestPayments	P30M
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23882634	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10715052
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14502841	shares
	us-gaap	Revenues Revenues	892870
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-103666
	us-gaap	Gross Profit GrossProfit	756634
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-9366146
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2078600
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	482108
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36451
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	92500
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7021
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-15581
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10675547
	us-gaap	Interest Paid InterestPaid	28622
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	29865
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	27148
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	64672
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1279630
	us-gaap	Net Income Loss NetIncomeLoss	-9395917
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	17979
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	29771
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17481
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2623
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1520862
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1264780
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3053858
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	136236
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25075
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3194202
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	521142
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1459990
	us-gaap	Share Based Compensation ShareBasedCompensation	1459990
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6095275
	us-gaap	Interest Expense InterestExpense	28622
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1565919
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7687457
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3662000
	us-gaap	Operating Expenses OperatingExpenses	11432181
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3699667
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-12558
	stem	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	46495
	stem	Increase Decrease In Accrued Interest And Other Receivables IncreaseDecreaseInAccruedInterestAndOtherReceivables	-46425
	stem	Share Based Compensation Impact On Basic And Diluted Earnings Per Share ShareBasedCompensationImpactOnBasicAndDilutedEarningsPerShare	0.06
	stem	Increase Decrease In Accrued Wind Down Expenses IncreaseDecreaseInAccruedWindDownExpenses	637045
	stem	Wind Down Expenses WindDownExpenses	45057
	stem	Revenue From Licensing Agreements And Grants RevenueFromLicensingAgreementsAndGrants	410762
CY2013Q2	stem	Approval Of Fund To Collaborators ApprovalOfFundToCollaborators	19300000
CY2012Q3	stem	Loan Term LoanTerm	P10Y
CY2006Q3	stem	Number Of Patients Violate Claims NumberOfPatientsViolateClaims	4	Claim
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24806769	shares
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
CY2012Q2	us-gaap	Revenues Revenues	248834
CY2012Q2	us-gaap	Gross Profit GrossProfit	184557
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	764654
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	210749
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11318
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2811
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5349753
CY2012Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-68738
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6183275
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	833522
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-68868
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-130
CY2012Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6205957
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	64277
CY2012Q2	us-gaap	Interest Expense InterestExpense	14175
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3749066
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	723445
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	5534310
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1775342
CY2012Q2	stem	Share Based Compensation Impact On Basic And Diluted Earnings Per Share ShareBasedCompensationImpactOnBasicAndDilutedEarningsPerShare	0.03
CY2012Q2	stem	Wind Down Expenses WindDownExpenses	9902
CY2012Q2	stem	Revenue From Licensing Agreements And Grants RevenueFromLicensingAgreementsAndGrants	38085
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.78
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39661934	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.00
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2013Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2086	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1714	shares
CY2013Q2	us-gaap	Revenues Revenues	281697
CY2013Q2	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	505000
CY2013Q2	us-gaap	Gross Profit GrossProfit	204124
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5864286
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	250364
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14040
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1790
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6221265
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4054
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	352583
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-5868682
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4396
CY2013Q2	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	4398
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	342
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-757688
CY2013Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	77573
CY2013Q2	us-gaap	Interest Expense InterestExpense	392855
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4804890
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	749641
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	6425389
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1581521
CY2013Q2	stem	Number Of Restricted Unit Would Vest Over Vesting Period NumberOfRestrictedUnitWouldVestOverVestingPeriod	2250000	shares
CY2013Q2	stem	Restricted Stock Units Vested Description After Specified Period RestrictedStockUnitsVestedDescriptionAfterSpecifiedPeriod	25	pure
CY2013Q2	stem	Number Of Restricted Unit Vest Over Next Fiscal Year NumberOfRestrictedUnitVestOverNextFiscalYear	25000	shares
CY2013Q2	stem	Additional Expense Recorded To Revise Estimated Reserve At Period End AdditionalExpenseRecordedToReviseEstimatedReserveAtPeriodEnd	0
CY2013Q2	stem	Number Of Restricted Units Vested During Period NumberOfRestrictedUnitsVestedDuringPeriod	11765	shares
CY2013Q2	stem	Share Based Compensation Impact On Basic And Diluted Earnings Per Share ShareBasedCompensationImpactOnBasicAndDilutedEarningsPerShare	0.02
CY2013Q2	stem	Wind Down Expenses WindDownExpenses	38978
CY2013Q2	stem	Revenue From Licensing Agreements And Grants RevenueFromLicensingAgreementsAndGrants	31333
CY2013Q2	stem	Restricted Stock Unit Vest Description RestrictedStockUnitVestDescription	2,250,000 of these restricted stock units will vest and convert into shares of our common stock over a four year period

Files In Submission

Name	View Source	Status
0001193125-13-324514-index-headers.html	Edgar Link	pending
0001193125-13-324514-index.html	Edgar Link	pending
0001193125-13-324514.txt	Edgar Link	pending
0001193125-13-324514-xbrl.zip	Edgar Link	pending
d570879d10q.htm	Edgar Link	pending
d570879dex311.htm	Edgar Link	pending
d570879dex312.htm	Edgar Link	pending
d570879dex321.htm	Edgar Link	pending
d570879dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R52.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R53.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R54.xml	Edgar Link	unprocessable
R55.htm	Edgar Link	pending
R55.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R56.xml	Edgar Link	unprocessable
R57.htm	Edgar Link	pending
R57.xml	Edgar Link	unprocessable
R58.htm	Edgar Link	pending
R58.xml	Edgar Link	unprocessable
R59.htm	Edgar Link	pending
R59.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R60.htm	Edgar Link	pending
R60.xml	Edgar Link	unprocessable
R61.htm	Edgar Link	pending
R61.xml	Edgar Link	unprocessable
R62.htm	Edgar Link	pending
R62.xml	Edgar Link	unprocessable
R63.htm	Edgar Link	pending
R63.xml	Edgar Link	unprocessable
R64.htm	Edgar Link	pending
R64.xml	Edgar Link	unprocessable
R65.htm	Edgar Link	pending
R65.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stem-20130630.xml	Edgar Link	completed
stem-20130630.xsd	Edgar Link	pending
stem-20130630_cal.xml	Edgar Link	unprocessable
stem-20130630_def.xml	Edgar Link	unprocessable
stem-20130630_lab.xml	Edgar Link	unprocessable
stem-20130630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBOT
Microbot Medical Inc. Stock $mbot

2013 Q3 Form 10-Q Financial Statement

#000119312513324514 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBOT Microbot Medical Inc. Stock $mbot

2013 Q3 Form 10-Q Financial Statement

#000119312513324514 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBOT
Microbot Medical Inc. Stock $mbot